Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 2 Ovarian Neoplasms 2 Melanoma 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Gastrointestinal Stromal Tumors 1 Gastro-enteropancreatic neuroendocrine tumor 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Cervical Cancer Metastatic 1 Carcinoma, Transitional Cell 1 BRCA-Mutated Breast Carcinoma 1 Advanced Solid Tumor 1

Interventions

Carboplatin 7 Pemetrexed 6 osimertinib 5 Drug Therapy 5 aflutinib 4 tislelizumab 3 anlotinib 3 Radiotherapy 3 Radiosurgery 3 Paclitaxel 3 Cisplatin 3 toripalimab 2 pembrolizumab 2 camrelizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 HM781-36B 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 famitinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × famitinib × Clear all

NCT05005468 2021-08-13

CAMFA-L

Shanghai Chest Hospital

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡